Loading...
Organometallic iridium arene compounds: the effects of C-donor ligands on anticancer activity
Lord, Rianne M. ; McGowan, P.C.
Lord, Rianne M.
McGowan, P.C.
Publication Date
2019-05
End of Embargo
Supervisor
Keywords
Rights
© 2019 The Chemical Society of Japan. All Rights Reserved. Reproduced in accordance with the publisher's self-archiving policy.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
06/04/2019
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
In the past decade, libraries of iridium organometallic arene compounds have expanded rapidly, with the majority of their applications aimed towards effective catalysts and potential anti-cancer drug candidates. Researchers have begun to adapt the traditional “piano-stool” structures to include different bidentate ligands, ancillary ligands and extend the aromaticity and functionality of the arene substituent, all in the hope to optimize their activities and allow the determination of structure activity relationships. Many of the complexes incorporate N- and O-donor ligands, but more recently, these structures have been expanded to include C-donor ligands such as cyclometalated bidentate ligands and N-heterocyclic carbenes. This mini-review highlights the recent and ongoing research in C-donor iridium arene complexes, and discusses their importance as potential anticancer drugs.
Version
Accepted manuscript
Citation
Lord RM and McGowan PC (2019) Organometallic iridium arene compounds: the effects of C-donor ligands on anticancer activity. Chemistry Letters. 48(8): 916-924.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article